Harnessing engineered cyanobacteria for next-generation therapeutics
Archives of Microbiology · 2026
DOI: 10.1007/s00203-026-04790-0 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Archives of Microbiology, 2026. Verfasst von Alka Bhardwaj und 1 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Microbial Genetics, Department of Botany, Institute of Science, Banaras Hindu University, Varanasi, 221005, India. Hauptthemen laut MEDLINE: Cyanobacteria, Metabolic Engineering. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 157 Literaturangaben. Gefördert von: Banaras Hindu University.
Abstract (Originalsprache)
Cyanobacteria are among the oldest photoautotrophic organisms and are recognized as key producers of structurally diverse secondary metabolites with significant pharmacological relevance. These organisms synthesize a wide range of bioactive compounds, including anticancer, neuroactive, anti-inflammatory, and antimicrobial metabolites, many of which exhibit unique mechanisms of action. Despite this potential, practical exploitation of cyanobacterial metabolites has historically been limited by slow growth rates, low product yields, and the frequent transcriptional silence of biosynthetic gene clusters under laboratory conditions. Recent advances in synthetic biology and metabolic engineering have begun to address these challenges. Tools such as CRISPR-based genome regulation, modular cloning platforms, optogenetic control systems, and heterologous expression strategies now enable targeted activation, regulation, and optimization of cyanobacterial biosynthetic pathways. These approaches facilitate access to cryptic metabolites, improve pathway control, and enhance production efficiency, thereby increasing the programmability of cyanobacterial systems. This review integrates current knowledge of cyanobacterial metabolite diversity with recent developments in pathway engineering, regulatory control, and systems-level optimization. Comparative evaluation of microbial production hosts highlights that cyanobacteria are not universal replacements for established heterotrophic systems but occupy complementary niches where photoautotrophic growth, low-input cultivation, and sustainability provide strategic advantages. We further discuss emerging opportunities for decentralized and small-batch biomanufacturing, while critically examining key technical, biosafety, and regulatory barriers that constrain translational deployment. Overall, advances in synthetic biology are progressively transforming cyanobacteria from underexplored natural product sources into programmable platforms for sustainable, biomarker-guided, and precision-oriented therapeutic manufacturing. Continued integration of engineering tools, bioprocess optimisation, and regulatory frameworks will be essential to expand the translational potential of cyanobacterial systems.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory of Microbial Genetics, Department of Botany, Institute of Science, Banaras Hindu University, Varanasi, 221005, India.
- Laboratory of Microbial Genetics, Department of Botany, Institute of Science, Banaras Hindu University, Varanasi, 221005, India. akmishraau@hotmail.com.
Förderung
- Banaras Hindu University
Zitieren
APA
Bhardwaj, A., & Mishra, A. K. (2026). Harnessing engineered cyanobacteria for next-generation therapeutics. Archives of Microbiology. https://doi.org/10.1007/s00203-026-04790-0
Vancouver
Bhardwaj A, Mishra AK. Harnessing engineered cyanobacteria for next-generation therapeutics. Archives of Microbiology. 2026. doi:10.1007/s00203-026-04790-0
BibTeX
@article{Bhardwaj2026,
author = {Bhardwaj, Alka and Mishra, Arun Kumar},
title = {Harnessing engineered cyanobacteria for next-generation therapeutics},
journal = {Archives of Microbiology},
year = {2026},
doi = {10.1007/s00203-026-04790-0}
}
EUVIMED